Insmed Inc. (INSM) announced Monday morning that the FDA has lifted the clinical hold previously placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.
Insmed gapped up sharply Monday and has continued to rise, with volume at over a 3-month high. The stock is now up 1.28 at $3.98 and has set over a month and a half high. Insmed has also re-crossed its 50-day moving average.
For comments and feedback: editorial@rttnews.com